• Repligen agreed to buy BioLife Solutions in a deal valuing the target at about $1.5 billion.
• BioLife holders to receive USD 11.25 cash plus 0.1442 Repligen shares per share, valued at USD 31.
• Consideration split: 64% stock, 36% cash; cash portion funded from cash on hand.
• Transaction expected to close in Q4 2026, subject to BioLife stockholder vote and customary conditions.
• Repligen projects at least USD 20 million synergies in year one, at least USD 30 million in year two.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Repligen Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607220600PRIMZONEFULLFEED9766145) on July 22, 2026, and is solely responsible for the information contained therein.